as on February 28, 2026 at 7:59 am IST
Day's Low
Day's High
1.52%
Downside
3.70%
Upside
52 Week's Low
52 Week's High
57.18%
Downside
105.01%
Upside
Check Intellia Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.7B
EPS (TTM)
-3.7095
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-4.59
Industry PE ratio
8.434504504504504
PEG Ratio
-0.0969
EBITDA
-468.8M
Revenue (TTM)
57.5M
Profit Margin
0.00%
Return On Equity TTM
-52.11%
Track how Intellia Therapeutics Inc. P/E has moved over time to understand its valuation trends.
Intellia Therapeutics Inc. in the last 5 years
Lowest (-45.06x)
September 30, 2021
Today (-4.59x)
February 28, 2026
Industry (8.43x)
February 28, 2026
Highest (-1.75x)
June 30, 2025
Today’s Price to Earnings Ratio: -4.59x
Compare market cap, revenue, PE, and other key metrics of Intellia Therapeutics Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.7B | -77.21% | -4.59 | 0.00% | |
| BUY | $43.9B | 124.79% | 142.78 | 8.45% | |
| BUY | $122.0B | 133.75% | 31.34 | 32.94% | |
| NA | $35.7B | NA | 619.94 | 1.38% | |
| BUY | $81.5B | 73.48% | 18.59 | 31.41% |
The Intellia Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Intellia Therapeutics Inc. investment value today
Current value as on today
₹1,40,635
Returns
₹40,635
(+40.64%)
Returns from Intellia Therapeutics Inc. Stock
₹36,571 (+36.57%)
Dollar Returns*
₹4,064 (+4.06%)
Based on 34 analysts
79.41%
Buy
20.59%
Hold
0.00%
Sell
Based on 34 analysts, 79.41% of analysts recommend a 'BUY' rating for Intellia Therapeutics Inc.. Average target price of $26.72
Get share price movements and forecasts by analysts on Intellia Therapeutics Inc..
What analysts predicted
48.43%UPSIDE
Target Price
$26.72
Current Price
$13.78
Analyzed by
34 Analysts
Target
$26.72
Intellia Therapeutics Inc. target price $26.72, a slight upside of 48.43% compared to current price of $13.78. According to 34 analysts rating.
Investment in Intellia Therapeutics Inc. Shares on INDmoney has dropped by -48.62% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Intellia Therapeutics Inc. Stock has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, NTLA stock has moved up by 9.0%
Best in 1 Year
![]()
In the last 1 year, NTLA has outperformed top 5 stocks with highest market-cap in its industry
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 73.9% return, outperforming this stock by 139.6%
Profit Down
![]()
Netprofit is down for the last 2 quarters, -101.25M → -101.32M (in $), with an average decrease of 0.1% per quarter
Revenue Fall
![]()
Revenue is down for the last 3 quarters, 16.62M → 13.78M (in $), with an average decrease of 8.8% per quarter
| Organisation | Intellia Therapeutics Inc. |
| Headquarters | 40 Erie Street, Cambridge, MA, United States, 02139 |
| Industry | Health Technology |
| CEO | Dr. John M. Leonard M.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Prof. Luciano Marraffini Ph.D. | Founder & Member of Scientific Advisor Board |
Dr. John M. Leonard M.D. | President, CEO & Director |
Mr. Michael P. Dube | VP, CAO & Principal Accounting Officer |
Dr. Rachel E. Haurwitz Ph.D. | Co-Founder |
Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board |
Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board |
Mr. Edward J. Dulac III | Executive Vice President, Chief Financial Officer and Treasurer |
Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary |
Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer |
Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board |
Intellia Therapeutics Inc. share price today is $13.78 as on at the close of the market. Intellia Therapeutics Inc. share today touched a day high of $14.29 and a low of $13.57.
Intellia Therapeutics Inc. share touched a 52 week high of $28.25 on and a 52 week low of $5.9 on . Intellia Therapeutics Inc. stock price today i.e. is closed at $13.78,which is 51.22% down from its 52 week high and 133.56% up from its 52 week low.
Intellia Therapeutics Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Intellia Therapeutics Inc. (NTLA) shares with as little as ₹91.026 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹910.26 in Intellia Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Intellia Therapeutics Inc. share’s latest price of $13.78 as on February 28, 2026 at 2:29 am IST, you will get 0.7257 shares of Intellia Therapeutics Inc.. Learn more about
fractional shares .
Intellia Therapeutics Inc. stock has given -77.21% share price returns and 23.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?